Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034201 | 0.84 | CYP19A1 (0.57) | CYP19A1POLBPKMKMT2A | |
| SCHEMBL17159812 | 0.82 | CYP19A1 (0.80) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL2728791 | 0.82 | CYP19A1 (0.57) | CYP19A1HDAC1HDAC6ATMLMNA | |
| SCHEMBL5655760 | 0.82 | KCNJ1 (0.54) | CYP19A1POLBPKMKMT2A | |
| SCHEMBL9525426 | 0.80 | KDM4E (0.50) | CYP19A1HDAC1HDAC6POLBPKM | |
| SCHEMBL15688800 | 0.77 | CYP19A1 (0.71) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL6280404 | 0.77 | PKM (0.49) | CYP19A1HDAC1HDAC6MAPTPKM | |
| SCHEMBL10247588 | 0.76 | CYP19A1 (0.59) | CYP19A1MAPTKDM4EHSP90AA1 | |
| SCHEMBL3235365 | 0.75 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL11354103 | 0.75 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062550-A1 | Process for the Large Scale Production of Rizatriptan Benzoate | MATRIX LABORATORIES LTD (IN) | 2009-03-05 | — | — | US | claimed |
| WO-2025262152-A1 | CONDUCTIVE POLYMER DISPERSIONS FOR IMPROVED STABILITY PERFORMANCE OF CAPACITORS | HERAEUS EPURIO GMBH (DE) | 2025-12-26 | — | — | WO | disclosed |
| EP-4668303-A1 | CONDUCTIVE POLYMER DISPERSIONS FOR IMPROVED STABILITY PERFORMANCE OF CAPACITORS | Heraeus Epurio GmbH (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-112004845-B | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate, and semiconductor device | 三菱瓦斯化学株式会社 | 2022-05-31 | — | — | CN | disclosed |
| US-20210277221-A1 | RESIN COMPOSITION, LAMINATE, SEMICONDUCTOR WAFER WITH RESIN COMPOSITION LAYER, SUBSTRATE FOR MOUNTING SEMICONDUCTOR WITH RESIN COMPOSITION LAYER AND SEMICONDUCTOR DEVICE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2021-09-09 | — | — | US | disclosed |
| EP-3786200-A1 | RESIN COMPOSITION, LAMINATE, RESIN COMPOSITION LAYER-ATTACHED SEMICONDUCTOR WAFER, SUBSTRATE FOR MOUNTING RESIN COMPOSITION LAYER-ATTACHED SEMICONDUCTOR, AND SEMICONDUCTOR DEVICE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2021-03-03 | — | — | EP | disclosed |
| CN-112004845-A | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer, and semiconductor device | 三菱瓦斯化学株式会社 | 2020-11-27 | — | — | CN | disclosed |
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-8431592-B2 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| EP-0651748-A1 | PROCESS FOR PREPARING INDOLE DERIVATIVES CONTAINING A 1,2,4-TRIAZOL-1-YL SUBSTITUENT. | MERCK SHARP & DOHME (GB) | 1995-05-10 | — | — | EP | disclosed |
| EP-0651749-A1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1995-05-10 | — | — | EP | disclosed |
| EP-0630374-A1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1994-12-28 | — | — | EP | disclosed |
| US-5298520-A | Triazole containing indole derivatives | MERCK SHARP & DOHME LIMITED (GB) | 1994-03-29 | — | — | US | disclosed |
| WO-1994002477-A1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| WO-1994002476-A1 | PROCESS FOR PREPARING INDOLE DERIVATIVES CONTAINING A 1,2,4-TRIAZOL-1-YL SUBSTITUENT | MERCK SHARP & DOHME LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| WO-1993025547-A1 | THE SULPHATE SALT OF A SUBSTITUTED TRIAZOLE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 1993-12-23 | — | — | WO | disclosed |
| EP-0573221-A1 | The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy | MERCK SHARP & DOHME LTD. (GB) | 1993-12-08 | — | — | EP | disclosed |
| WO-1993018029-A1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1993-09-16 | — | — | WO | disclosed |
| EP-0497512-A2 | Imidazole, triazole and tetrazole derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062550-A1 | Process for the Large Scale Production of Rizatriptan Benzoate | DPP4, HTR3A, SI | CYP19A1 2017/4885HDAC1 107/4885HDAC6 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.